Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...

Check the time stamp on this data. Updated AI-Generated Signals for Gilead Sciences Inc. (GILD) available here: GILD.

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on GILD: Gilead Sciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

With FDA approval in the bag for its AI-based aortic stenosis diagnostic tool, Echo IQ is focused on commercialisation over the coming years.

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...